Dr. Timothy Cripe of Nationwide Childrens Hospital Appointed to a Committee of the Food and Drug Administration

May 8, 2012

Timothy Cripe, MD, PhD, chief of Hematology/Oncology/Bone Marrow Transplantation at Nationwide Children’s Hospital, was recently appointed a member of the Cellular, Tissue and Gene Therapy Advisory Committee which reports to the Food and Drug Administration (FDA).

This committee provides guidance to the FDA in approving novel cellular, tissue and gene therapy therapeutics and devices. In recent years, the committee reviewed applications for the new cancer immunotherapy Sipuleucel-T (Provenge) and the first licensed cord blood product, HEMACORD. The committee is also charged with reviewing applications that use embryonic stem cells or other cellular therapies.

Such committees of the FDA are established to provide functions which support its mission of protecting and promoting the public health, while meeting the requirements set forth in the Federal Advisory Committee Act. The FDA has 32 Advisory Committees across all Centers which are subject to renewal at two-year intervals unless the committee charter states otherwise. They are advisory in nature with the FDA making final decisions.

Dr. Cripe recently came to Nationwide Children’s from Cincinnati Children’s Hospital Medical Center where he served as medical co-director in Clinical and Translational Research and was the founding director of the Comprehensive Musculoskeletal Tumor Program. During his stint at Cincinnati, he was a professor of Pediatrics and Director of Pilot and Collaborative Studies in the Center for Clinical and Translational Science and Training.

His clinical interests include gene and viral therapies for solid tumors in children, including brain tumorsneuroblastoma and bone and soft tissue sarcomas. Dr. Cripe’s current research focuses on developing and testing new, targeted therapies for pediatric solid tumors and translating those findings into clinical studies. He also investigates the use of viruses that selectively infect and kill cancer cells, studies their utility for killing cancer stem cells, and was among the first in the country to launch clinical trials of attenuated viruses in children.

Dr. Cripe is a magna cum laude graduate of Princeton University and completed his MD, PhD in genetics and pediatric residency training at the University of Iowa. He was a fellow in pediatric hematology/oncology at the Children’s Hospital and the Dana-Farber Cancer Institute in Boston, and at the Children’s Hospital and University of Colorado Health Sciences Center in Denver. 

Following his subspecialty training, he was an assistant professor of Pediatrics at the University of Wisconsin Children’s Hospital and Comprehensive Cancer Center in Madison and was the pediatric medical director of the UW/American Red Cross Hemophilia Treatment Center.

NOTE TO EDITOR:  Dr. Cripe is a resident of Dublin 43017.

Dr. Timothy Cripe, chief of Hematology/Oncology/Bone Marrow Transplantation

About Nationwide Children's Hospital

Named to the Top 10 Honor Roll on U.S. News & World Report’s 2019-20 list of “Best Children’s Hospitals,” Nationwide Children’s Hospital is one of America’s largest not-for-profit freestanding pediatric health care systems providing wellness, preventive, diagnostic, treatment and rehabilitative care for infants, children and adolescents, as well as adult patients with congenital disease. Nationwide Children’s has a staff of more than 13,000 providing state-of-the-art pediatric care during more than 1.5 million patient visits annually. As home to the Department of Pediatrics of The Ohio State University College of Medicine, Nationwide Children’s physicians train the next generation of pediatricians and pediatric specialists. The Abigail Wexner Research Institute at Nationwide Children’s Hospital is one of the Top 10 National Institutes of Health-funded freestanding pediatric research facilities. More information is available at NationwideChildrens.org.